Objective-Soluble fms-like tyrosine kinase 1 (sFlt1) is involved in the pathophysiology of preeclampsia and coronary artery disease.
S oluble fms-like tyrosine kinase 1 (sFlt1) is a circulating splice variant of cell-bound vascular endothelial growth factor receptor-1. sFlt1 is increased in preeclampsia. 1 sFlt1 can induce endothelial dysfunction and thereby may contribute to cardiovascular disease. 2, 3 sFlt1 is produced by endo-thelial cells. 4 In mice, sFlt1 levels significantly increased within 30 minutes after coronary occlusion. 3 Coronary endothelial cells increased sFlt1 expression within 60 minutes of hypoxia. 2 The fourth, Ig-like, loop of the extracellular sFlt1 domain has a high-affinity heparin binding site, and several The time point showing values directly after CA/PCI is divided into CA only (single-dose heparin) and PCI (second dose). nϭ135, Pϭ0.0009. In patients with high sFlt1 values before PCI, blood was drawn after heparin administration. B, Placental growth factor (PLGF) and vascular endothelial growth factor (VEGF) before and after heparin and sFlt1/PLGF and sFlt1/VEGF ratios. nϭ20, *PϽ0.0001 and †PϽ0.05 vs at admission.
clinical studies have shown that sFlt1 increases after heparin treatment. [5] [6] [7] We reasoned that heparin administration might influence sFlt levels by displacing heparan-bound sFlt1 from the extracellular matrix.
Materials and Methods
We enrolled 135 consecutive patients scheduled for elective coronary angiography (CA) and percutaneous coronary intervention (PCI) (Deutsches Register für Klinische Studien, DRKS00000278). Patients received intravenous unfractionated (5000 -10 000 U) hep-arin during the procedure. We collected serial blood samples and measured sFlt1 and placental growth factor using 2-step chemiluminescent microparticle sandwich immunoassays (Abbott Diagnostics). Human umbilical cords were incubated with either 5 mL of heparin (1 IU/mL) for 10 minutes, 5 mL of heparinase I and III (each 0.4 U/mL) for 30 minutes, or 5 mL of PBS. Our isolation and culture techniques have been described. 8 Male C57BL/6 mice (Charles River) were treated with 20 IU IV or SC heparin or vehicle, and their serum was used for tube formation. Additional methods are described in the supplemental material, available online at http://atvb.ahajournals.org. 
Results
In coronary artery disease patients, the median sFlt1 level at admission was 254 pg/mL. sFlt levels increased more than 50-fold to a median value of 13 440 pg/mL directly after CA/PCI ( Figure 1A ). Within 6 to 10 hours, sFlt1 values returned to baseline and remained stable after 12 to 24 hours. sFlt1 levels were higher in patients receiving a second heparin bolus during PCI than in patients with CA only. Figure 1B shows an elevated placental growth factor level after heparin; the sFlt1/placental growth factor ratio shows a shift to an antiangiogenic state. Figure 1B also shows a reduced vascular endothelial growth factor level directly after CA/PCI, corresponding to the high sFlt1/vascular endothelial growth factor ratio. Elevated sFlt1 levels were not related to microparticles or cell debris, as ultracentrifugation did not affect the levels (Supplemental Figure  I) . sFlt1 isoforms are shown by Western blot. Soluble endoglin, soluble vascular endothelial growth factor receptor-2, and endothelial protein C receptor were not elevated by heparin. Platelet activation did not occur (Supplemental Figure III) . In umbilical veins, heparin and heparinase IϩIII both induced sFlt1 release (Figure 2A ). Immunofluorescence confirmed sFlt1 release from endothelium ( Figure 2B ). Low-molecular-weight heparin led to similar effects (Supplemental Figure IV) . In endothelial cells, heparin doubled sFlt1 concentrations in the medium (Supplemental Figure V) . Figure 2C shows elevated sFlt1 in mouse plasma after intravenous or subcutaneous heparin treatment at different time points. Serum from these mice reduced endothelial cell tube formation in culture ( Figure 2D , quantified in Figure 2E ).
Discussion
Our study supports the hypothesis that heparin induces an antiangiogenic state by releasing sFlt1. In coronary artery disease patients receiving heparin during CA and PCI, sFlt1 values increased 50-fold shortly after heparin administration. Heparin induces an antiangiogenic state by releasing sFlt1, which is bound to heparan sulfate proteoglycans. sFlt1 is released on heparin treatment because of competitive binding at its heparin binding site. This finding could be relevant in diseases with impaired angiogenesis, such as preeclampsia, cancer, and coronary artery disease. Recently, Sela et al reported that local retention and systemic release of sFlt1 are both mediated by heparin binding and regulated by heparanase. 9 The combined data suggest that a widely used therapeutic agent might influence angiogenesis.
Sela et al induced sFlt1 secretion from vascular smooth muscle cells and human placental villous explants with heparin. 9 They also found increased sFlt1 levels in 5 pregnant women receiving low-molecular-weight heparin and detected heparanase in the syncytiotrophoblasts and placental syncytial knots, which produce sFlt1. In addition to showing marked sFlt1 increases in a large cohort, we showed that serum from heparintreated animals effects endothelial cells. The combined data underscore the conclusion a commonly used therapeutic agent could influence the capability to make new blood vessels.
Maynard et al first reported increased plasma sFlt1 levels in preeclamptic women and increased sFlt1 mRNA in placentas, and they were also able to show that sFlt1 inhibits endothelial tube formation by blocking placental growth factor and vascular endothelial growth factor. 10 sFlt1 has recently become of interest to cardiologists because elevated levels of it are associated with myocardial ischemia, coronary occlusion, and acute coronary syndromes. 5, 6, 11 Heparin is commonly used in these patients.
Clinical consequences are speculative. However, heparin not only might affect sFlt1 measurement in patients under heparin treatment but also could have pathophysiological effects. Many patients in whom angiogenesis and sFlt1 levels are relevant receive longer-term heparin treatment, such as cancer patients with venous thromboembolism, pregnant women with premature labor, a wide range of patients with cardiac diseases, and patients undergoing hemodialysis. Further research will be necessary to explore clinical ramifications.
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